Table 1.
Completed clinical trials of approved PD-1/PD-L1 inhibitors in combination with other approved treatment strategy
| Target | Checkpoint inhibitors | Combined intervention | Combined category | Conditions | Phase | Trial number |
|---|---|---|---|---|---|---|
| PD-1 | Nivolumab | Tivozanib | Anti-angiogenesis therapy | RCC | Phase 1, 2 | NCT03136627 |
| Cabozantinib | Anti-angiogenesis therapy | Breast cancer | Phase 2 | NCT03316586 | ||
| Bevacizumab | Anti-angiogenesis therapy | Hepatocellular carcinoma | Phase 2 | NCT04393220 | ||
| Carotuximab | Anti-angiogenesis therapy | NSCLC | Phase 1 | NCT03181308 | ||
| Pomalidomide | Anti-angiogenesis therapy | Nervous system lymphoma | Phase 1 | NCT03798314 | ||
| Ramucirumab | Anti-angiogenesis therapy | Gastric cancer; GEJ Cancer | Phase 1, 2 | NCT02999295 | ||
| Pazopanib + sunitinib + ipilimumab | Anti-angiogenesis therapy + targeted therapy (multiple kinases) + CTLA-4 antibody | RCC | Phase 1 | NCT01472081/CheckMate 016 | ||
| Pemetrexed + paclitaxel + veliparib + carboplatin | Chemotherapy | NSCLC | Phase 1 | NCT02944396 | ||
| Bendamustine hydrochloride | Chemotherapy | Hodgkin's lymphoma | Phase 1, 2 | NCT03343652 | ||
| Idarubicin + cytarabine + solu-medrol + dexamethasone | Chemotherapy | AML | Phase 1, 2 | NCT02464657 | ||
| Carboplatin + pemetrexed + ipilimumab | Chemotherapy + CTLA-4 antibody | NSCLC | Phase 2 | NCT03256136 | ||
| TG4010 + chemotherapy | Chemotherapy + Other treatment | NSCLC | Phase 2 | NCT03353675 | ||
| Cyclophosphamide + fludarabine + TIL infusion + interleukin-2 + ipilimumab | Chemotherapy + other treatment + CTLA-4 antibody | Ovarian Cancer | Phase 1, 2 | NCT03287674 | ||
| PD-1 | Nivolumab | Ipilimumab | CTLA-4 antibody | Melanoma | Phase 1 | NCT01621490 |
| Ipilimumab | CTLA-4 antibody | Melanoma | Phase 3 | NCT02599402 | ||
| Ipilimumab | CTLA-4 antibody | Melanoma | Phase 2 | NCT02320058 | ||
| Ipilimumab | CTLA-4 antibody | ED-SCLC | Phase 3 | NCT02538666 | ||
| Ipilimumab | CTLA-4 antibody | Melanoma | Phase 3 | NCT02714218 | ||
| Ipilimumab | CTLA-4 antibody | Melanoma | Phase 3 | NCT03068455 | ||
| Ipilimumab | CTLA-4 antibody | Urothelial carcinoma | Phase 1 | NCT03387761 | ||
| Ipilimumab | CTLA-4 antibody | RCC | Phase 2 | NCT03029780 | ||
| Ipilimumab | CTLA-4 antibody | MPM | Phase 2 | NCT02716272 | ||
| Ipilimumab | CTLA-4 antibody | Melanoma | n.a | NCT03438279 | ||
| Ipilimumab | CTLA-4 antibody | Melanoma | Phase 1, 2 | NCT02941744 | ||
| Ipilimumab | CTLA-4 antibody | Melanoma | Phase 2 | NCT02731729 | ||
| Ipilimumab | CTLA-4 antibody | Malignant pleural mesothelioma | Phase 2 | NCT03048474 | ||
| Ipilimumab | CTLA-4 antibody | Melanoma | Phase 2 | NCT01783938/CheckMate 064 | ||
| Ipilimumab | CTLA-4 antibody | Cancer | NCT03165409 | |||
| Ipilimumab + SBRT | CTLA-4 antibody + radiotherapy | RCC; kidney cancer | Phase 2 | NCT03065179 | ||
| Ipilimumab + radiotherapy | CTLA-4 antibody + radiotherapy | Melanoma | Phase 1 | NCT02659540 | ||
| Ipilimumab + surgery | CTLA-4 antibody + surgery | Head and neck carcinoma | Phase 1, 2 | NCT03003637 | ||
| Ipilimumab + enzalutamide | CTLA-4 antibody + targeted therapy (AR) | Prostate cancer | Phase 2 | NCT02601014 | ||
| Interferon γ | Other treatment | Solid tumor | Phase 1 | NCT02614456 | ||
| Interleukin-2 | Other treatment | RCC | Phase 1, 2 | NCT02989714 | ||
| PD-1 | Nivolumab | Tumor biopsy specimens + blood samples | Other treatment | Melanoma | n.a | NCT03348891 |
| JS001 + pembrolizumab | PD-1 antibody | Carcinoma; hepatocellular | Phase 2 | NCT03939975 | ||
| BDCA-1 + myDC + avelumab + ipilimumab | PD-L1 antibodies + CTLA-4 antibody + Other treatment | Solid tumor | Phase 1 | NCT03707808 | ||
| Mogamulizumab | Targeted therapy (CCR4) | Solid tumor | Phase 1 | NCT02476123 | ||
| Mogamulizumab | Targeted therapy (CCR4) | Solid tumor | Phase 1, 2 | NCT02705105 | ||
| Mogamulizumab | Targeted therapy (CCR4) | Solid cancer | Phase 1 | NCT02946671 | ||
| Brentuximab vedotin | Targeted therapy (CD30) | Hodgkin lymphoma | Phase 1, 2 | NCT02572167 | ||
| Brentuximab vedotin | Targeted therapy (CD30) | Hodgkin lymphoma | Phase 3 | NCT03138499 | ||
| Daratumumab | Targeted therapy (CD38) | NSCLC;TNBC | Phase 1, 2 | NCT03098550 | ||
| X4P-001 | Targeted therapy (CXCR4) | RCC | Phase 1, 2 | NCT02923531 | ||
| Cetuximab + cisplatin + radiotherapy | Targeted therapy (EGFR) + chemotherapy + radiotherapy | Squamous cell head and neck cancer | Phase 3 | NCT03349710 | ||
| Entinostat | Targeted therapy (HDAC) | Cholangiocarcinoma; pancreatic adenocarcinoma | Phase 2 | NCT03250273 | ||
| Vopratelimab + ipilimumab + pembrolizumab | Targeted therapy (ICOS) + CTLA-4 antibody + PD-1 antibody | Solid tumor | Phase 1, 2 | NCT02904226 | ||
| Binimetinib + ipilimumab | Targeted therapy (MEK1/2) + CTLA-4 antibody | Colorectal cancer | Phase 2 | NCT03271047 | ||
| Regorafenib | Targeted therapy (multiple kinases) | Solid tumor | Phase 1, 2 | NCT03406871 | ||
| PD-1 | Nivolumab | Dasatinib | Targeted therapy (multiple kinases) | Myeloid leukemia | Phase 1 | NCT02011945 |
| BBI503 + doxorubicin + pembrolizumab + paclitaxel + sunitinib | Targeted therapy (multiple kinases) + Chemotherapy | Cancer | Phase 1 | NCT02483247 | ||
| Omaveloxolone capsules + ipilimumab | Targeted therapy (NF-κB) + CTLA-4 antibody | Melanoma | Phase 1, 2 | NCT02259231 | ||
| INCAGN01949 + ipilimumab | Targeted therapy (OX40) + CTLA-4 antibody | Malignancy | Phase 1, 2 | NCT03241173 | ||
| Elotuzumab + pomalidomide + dexamethasone | Targeted therapy (SLAMF7) | Myeloma | Phase 2 | NCT02612779 | ||
| BBI608 + ipilimumab + pembrolizumab | Targeted therapy (STAT3) + CTLA-4 antibody + PD-1 antibody | Cancer | Phase 1 | NCT02467361 | ||
| DV281 + breath actuated nebulizer | Targeted therapy (TLR) + other treatment | NSCLC | Phase 1 | NCT03326752 | ||
| DS-8273a | Targeted therapy (TRAIL-R2) | Melanoma | Phase 1 | NCT02983006 | ||
| Pembrolizumab | Bevacizumab | Anti-angiogenesis therapy | RCC | Phase 1, 2 | NCT02348008 | |
| Anlotinib | Anti-angiogenesis therapy | NSCLC | Phase 1, 2 | NCT04670107 | ||
| Pazopanib | Anti-angiogenesis therapy | RCC | Phase 1 | NCT02014636/KEYNOTE-018 | ||
| Lenalidomide | Anti-angiogenesis therapy | Blood Cancer | Phase 1 | NCT01953692/KEYNOTE-013 | ||
| Bevacizumab | Anti-angiogenesis therapy | GBM | Phase 2 | NCT02337491 | ||
| Bevacizumab + cyclophosphamide | Anti-angiogenesis therapy + chemotherapy | Ovarian cancer; fallopian tube cancer; peritoneal cancer | Phase 2 | NCT02853318 | ||
| Doxorubicin | Chemotherapy | Endometrial cancer | Phase 2 | NCT03276013 | ||
| mFOLFOX6 | Chemotherapy | Colorectal cancer | Phase 2 | NCT02375672 | ||
| PD-1 | Pembrolizumab | Nab-paclitaxel | Chemotherapy | NSCLC | Phase 1, 2 | NCT02733250 |
| Azacitidine | Chemotherapy | Colorectal cancer | Phase 2 | NCT02260440 | ||
| Nab-paclitaxel + epirubicin + cyclophosphamide | Chemotherapy | TNBC | Phase 2 | NCT03289819 | ||
| Nab-paclitaxel + doxorubicin + cyclophosphamide + carboplatin + paclitaxel | Chemotherapy | TNBC | Phase 1 | NCT02622074/KEYNOTE-173 | ||
| Oxaliplatin + capecitabine | Chemotherapy | BTC | Phase 2 | NCT03111732 | ||
| Docetaxel | Chemotherapy | NSCLC | Phase 2 | NCT02574598 | ||
| Pemetrexed + carboplatin + cisplatin | Chemotherapy | NSCLC | Phase 2 | NCT03664024/KEYNOTE-782 | ||
| Carboplatin + cisplatin + etoposide | Chemotherapy | SCLC | Phase 3 | NCT03066778 | ||
| Decitabine | Chemotherapy | Myeloid leukemia | Phase 1, 2 | NCT02996474 | ||
| Cisplatin + 5-FU + capecitabine | Chemotherapy | Gastric cancer; gastroesophageal junction adenocarcinoma | Phase 2 | NCT02335411/KEYNOTE-059 | ||
| Chemotherapy | Chemotherapy | Gastric cancer | Phase 2 | NCT02918162 | ||
| Doxorubicin hydrochloride | Chemotherapy | Sarcoma | Phase 1, 2 | NCT02888665 | ||
| Carboplatin | Chemotherapy | Ovarian cancer; fallopian tube cancer; peritoneal cancer | Phase 1, 2 | NCT03029598 | ||
| Cyclophosphamide | Chemotherapy | MBC | Phase 2 | NCT03139851 | ||
| PD-1 | Pembrolizumab | Paclitaxel + carboplatin + bevacizumab + pemetrexed + ipilimumab + erlotinib + gefitinib | Chemotherapy + anti-angiogenesis therapy + CTLA-4 antibody + targeted therapy (EGFR) | NSCLC | Phase 1, 2 | NCT02039674/KEYNOTE-021 |
| Cisplatin + pemetrexed + carboplatin + paclitaxel + nab-paclitaxel + ipilimumab + etoposide + pegfilgrastim | Chemotherapy + CTLA-4 antibody + other treatment | NSCLC; SCLC | Phase 1 | NCT01840579 | ||
| Niraparib + dostarlimab | Chemotherapy + PD-1 antibody | NSCLC | Phase 2 | NCT03308942 | ||
| Cyclophosphamide + doxorubicin hydrochloride + prednisone + rituximab + vincristine sulfate | Chemotherapy + Targeted therapy (CD20) | Lymphoma | Phase 1 | NCT02541565 | ||
| PegIFN-2b + ipilimumab | CTLA4 antibody + other treatment | RCC; Melanoma | Phase 1, 2 | NCT02089685/KEYNOTE-29 | ||
| Talimogene laherparepvec | Oncolytic virus therapy | Squamous cell carcinoma of the head and neck | Phase 1 | NCT02626000/KEYNOTE-137 | ||
| alfa-2b (HDI) | Other treatment | Melanoma | Phase 1 | NCT02339324 | ||
| Pegzilarginase | Other treatment | SCLC | Phase 1, 2 | NCT03371979 | ||
| PegIFN-2b | Other treatment | Melanoma | Phase 1 | NCT02112032 | ||
| Sintilimab | PD-1 antibody | NSCLC | n.a | NCT05059951 | ||
| SABR | Radiotherapy | Breast cancer | Phase 1 | NCT02303366 | ||
| Radiation therapy | Radiotherapy | Malignancy | Phase 1 | NCT02987166 | ||
| Radiation therapy | Radiotherapy | RCC | Phase 2 | NCT02599779 | ||
| SBRT | Radiotherapy | Urothelial cancer | Phase 1 | NCT02826564 | ||
| PD-1 | Pembrolizumab | Intensity modulated radiation therapy | Radiotherapy | Squamous cell carcinoma of the head and neck | Phase 2 | NCT03057613 |
| SABR | Radiotherapy | RCC | Phase 1, 2 | NCT02855203 | ||
| Radiotherapy | Radiotherapy | Cancer | Phase 1 | NCT02303990 | ||
| Hypofractionated stereotactic irradiation (HFSRT) + bevacizumab | Radiotherapy + anti-angiogenesis therapy | Glioma | Phase 1 | NCT02313272 | ||
| Radiation therapy + cisplatin | Radiotherapy + chemotherapy | Squamous cell carcinoma | Phase 1, 2 | NCT02759575 | ||
| Docetaxel + doxorubicin hydrochloride + intensity-modulated radiation therapy + therapeutic conventional surgery | Radiotherapy + chemotherapy + surgery | Thyroid cancer | Phase 2 | NCT03211117 | ||
| Brachytherapy | Radiotherapy + other treatment | Esophageal cancer | Phase 1 | NCT02642809 | ||
| Radiation + Vitamin D + aspirin + lansoprazole + cyclophosphamide + curcumin | Radiotherapy + other treatment + chemotherapy + targeted therapy (p300/CREB) | Cervical cancer; uterine cancer | Phase 2 | NCT03192059 | ||
| Radiotherapy + rituximab + autologous dendritic cells + GM-CSF | Radiotherapy + targeted therapy (CD20) + other treatment | Follicular lymphoma | Phase 2 | NCT02677155 | ||
| SBRT + trametinib | Radiotherapy + targeted therapy(MEK1/2) | Pancreatic cancer | Phase 2 | NCT02704156 | ||
| Dabrafenib + trametinib | Targeted therapy (BRAF) + targeted therapy (MEK) | Melanoma | Phase 1, 2 | NCT02130466/KEYNOTE-022 | ||
| PD-1 | Pembrolizumab | Acalabrutinib | Targeted therapy (BTK) | Ovarian cancer | Phase 2 | NCT02537444/KEYNOTE191 |
| Acalabrutinib | Targeted therapy (BTK) | Head and neck squamous cell carcinoma | Phase 2 | NCT02454179 | ||
| Acalabrutinib | Targeted therapy (BTK) | NSCLC | Phase 2 | NCT02448303 | ||
| Maraviroc | Targeted therapy (CCR5) | Colorectal cancer | Phase 1 | NCT03274804 | ||
| Abemaciclib + gemcitabine + ramucirumab + samotolisib | Targeted therapy (CDK) + chemotherapy + anti-angiogenesis therapy + targeted therapy (PI3K) | NSCLC | Phase 1 | NCT02079636 | ||
| Necitumumab | Targeted therapy (EGFR) | NSCLC | Phase 1 | NCT02451930 | ||
| Afatinib | Targeted therapy (EGFR) | Squamous cell carcinoma of the lung | Phase 2 | NCT03157089 | ||
| PEGPH20 | Targeted therapy (HA) | Solid tumor | Phase 1 | NCT02563548 | ||
| Entinostat | Targeted therapy (HDAC) | Solid tumor | Phase 1 | NCT02909452 | ||
| Vismodegib | Targeted therapy (hedgehog) | Basal cell skin cancer | Phase 1, 2 | NCT02690948 | ||
| Margetuximab | Targeted therapy (HER2) | Gastric cancer; gastroesophageal junction cancer | Phase 1, 2 | NCT02689284 | ||
| Eribulin mesylate | Targeted therapy (microtubule) | TNBC | Phase 1, 2 | NCT02513472 | ||
| Eribulin | Targeted therapy (microtubule) | HR + /HER2- MBC | Phase 2 | NCT03222856 | ||
| Anlotinib | Targeted therapy (multiple kinases) | Ovarian cancer | n.a | NCT05188781 | ||
| Axitinib | Targeted therapy (multiple kinases) | RCC | Phase 1 | NCT02133742 | ||
| Lenvatinib | Targeted therapy (multiple kinases) | Gastric cancer | Phase 2 | NCT03609359 | ||
| Lenvatinib | Targeted therapy (multiple kinases) | Solid tumor | Phase 1 | NCT03006887 | ||
| PD-1 | Pembrolizumab | Saroglitazar | Targeted therapy (multiple kinases) | Biliary cancer | Phase 2 | NCT02703714 |
| Niraparib | Targeted therapy (PARP) | TNBC; ovarian cancer | Phase 1, 2 | NCT02657889 | ||
| Ibrutinib | Targeted therapy (brutons tyrosine kinase) | Non-Hodgkin lymphoma | Phase 1 | NCT02950220 | ||
| Ibrutinib + everolimus + docetaxel + paclitaxel + cetuximab | Targeted therapy (brutons tyrosine kinase) + targeted therapy (mTOR) + targeted therapy (EGFR) + chemotherapy | Gastric adenocarcinoma; genitourinary adenocarcinoma | Phase 1, 2 | NCT02599324 | ||
| Afatinib dimaleate | Targeted therapy (EGFR) | NSCLC | Phase 1 | NCT02364609 | ||
| Platinum + afatinib | Targeted therapy (EGFR) + chemotherapy | Squamous Cell Carcinoma of the Lung | NCT04552535 | |||
| Pemigatinib + gemcitabine + cisplatin + docetaxel + trastuzumab | Targeted therapy (FGFR) + targeted therapy (HER2) + chemotherapy | Malignancies | Phase 1, 2 | NCT02393248 | ||
| ImmunoPulse IL-12 | Targeted therapy (IL-12) | Melanoma | Phase 2 | NCT02493361 | ||
| Encorafenib + binimetinib | Targeted therapy (RAF) + targeted therapy (MEK1/2) | Melanoma | Phase 1, 2 | NCT02902042 | ||
| IMP321 (eftilagimod alpha) | Targeted therapy (soluble LAG-3 protein) | Melanoma | Phase 1 | NCT02676869 | ||
| Lenalidomide + dexamethasone | Targeted therapy (TNF-α) | Myeloma | Phase 2 | NCT02880228 | ||
| Paricalcitol | Targeted therapy (vitamin D receptor) | Pancreatic cancer | Phase 2 | NCT03331562 | ||
| Cemiplimab | Ipilimumab | CTLA-4 antibody | Lung cancer | Phase 2 | NCT03430063 | |
| Ipilimumab + chemotherapy | CTLA-4 antibody + chemotherapy | Lung cancer | Phase 3 | NCT03515629 | ||
| PD-1 | Cemiplimab | Hypofractionated radiotherapy + cyclophosphamide + docetaxel + carboplatin + GM-CSF + paclitaxel + pemetrexed | Radiotherapy + chemotherapy | Malignancy | Phase 1 | NCT02383212 |
| Isatuximab | Targeted therapy (CD38) | Malignancy | Phase 1, 2 | NCT03367819 | ||
| PD-L1 | Atezolizumab | Anlotinib | Anti-angiogenesis therapy | NSCLC | Phase 1, 2 | NCT04670107 |
| Bevacizumab + carboplatin + paclitaxel | Anti-angiogenesis therapy + chemotherapy | NSCLC | Phase 3 | NCT02366143 | ||
| Bevacizumab + gemcitabine + leucovorin + Nab-paclitaxe + oxaliplatin + capecitabine + cisplatin | Anti-angiogenesis therapy + chemotherapy | Solid tumor | Phase 1 | NCT02715531 | ||
| Bevacizumab + interferon alfa-2b + PEG-interferon alfa-2a + ipilimumab + obinutuzumab | Anti-angiogenesis therapy + CTLA-4 antibody + targeted therapy (CD20) + other treatment | Solid tumor | Phase 1 | NCT02174172 | ||
| Bevacizumab + cobimetinib | Anti-angiogenesis therapy + targeted therapy (MEK1) | Gastrointestinal tumor | Phase 1 | NCT02876224 | ||
| Bevacizumab + sunitinib | Anti-angiogenesis therapy + targeted therapy (RTK) | RCC | Phase 2 | NCT01984242 | ||
| Bevacizumab + sunitinib | Anti-angiogenesis therapy + targeted therapy (RTK) | RCC | Phase 3 | NCT02420821 | ||
| PD-L1 | Atezolizumab | 5-FU + bevacizumab + carboplatin + leucovorin + nab-paclitaxel + oxaliplatin + paclitaxel + pemetrexed | Chemotherapy + anti-angiogenesis therapy | Solid tumor | Phase 1 | NCT01633970 |
| Azacitidine | Chemotherapy | Myelodysplastic syndromes | Phase 1 | NCT02508870 | ||
| Nab-Paclitaxel | Chemotherapy | TNBC | Phase 3 | NCT02425891/IMpassion130 | ||
| Carboplatin + pemetrexed | Chemotherapy | NSCLC | Phase 3 | NCT02367781 | ||
| Carboplatin + nab-paclitaxel + paclitaxel | Chemotherapy | NSCLC | Phase 3 | NCT02367794/IMpower131 | ||
| Carboplatin + cyclophosphamide | Chemotherapy | Breast cancer; cervix cancer; ovarian cancer; endometrial cancer | Phase 1 | NCT02914470 | ||
| Carboplatin + paclitaxel + bevacizumab | Chemotherapy + anti-angiogenesis therapy | Ovarian cancer | Phase 1, 2 | NCT03394885 | ||
| Bendamustine + cyclophosphamide + doxorubicin + obinutuzumab + prednisone + vincristine + rituximab | Chemotherapy + targeted therapy (CD20) | DLBCL | Phase 1, 2 | NCT02596971 | ||
| Carboplatin + docetaxel + pertuzumab + trastuzumab + trastuzumab emtansine + doxorubicin + cyclophosphamide | Chemotherapy + targeted therapy (HER2) | TNBC | Phase 1 | NCT02605915 | ||
| PD-L1 | Atezolizumab | Talimogene laherparepvec | Oncolytic virus therapy | TNBC; colorectal cancer | Phase 1 | NCT03256344 |
| Radium-223 dichloride | Radiotherapy | CRPC | Phase 1 | NCT02814669 | ||
| HFRT | Radiotherapy | NSCLC | Early Phase 1 | NCT02463994 | ||
| Ciforadenant | Targeted therapy (adenosine A2A receptor) | Cancer | Phase 1 | NCT02655822 | ||
| Alectinib | Targeted therapy (ALK) | NSCLC | Phase 1 | NCT02013219 | ||
| Obinutuzumab + polatuzumab vedotin + rituximab | Targeted therapy (CD20) + targeted therapy (CD79b) | Lymphoma | Phase 1, 2 | NCT02729896 | ||
| Daratumumab | Targeted therapy (CD38) | NSCLC | Phase 1, 2 | NCT03023423 | ||
| Daratumumab + lenalidomide + pomalidomide + dexamethasone | Targeted therapy (CD38) + targeted therapy (TNF-α) | Myeloma | Phase 1 | NCT02431208 | ||
| Gilteritinib | Targeted therapy (FLT3/AXL) | AML | Phase 1, 2 | NCT03730012 | ||
| Trastuzumab emtansine | Targeted therapy (HER2) | MBC | Phase 2 | NCT02924883 | ||
| Cobimetinib | Targeted therapy (MEK1) | Solid Tumor | Phase 1 | NCT01988896 | ||
| Cobimetinib + Paclitaxel + nab-paclitaxel | Targeted therapy (MEK1) + chemotherapy | TNBC | Phase 2 | NCT02322814 | ||
| Cobimetinib + regorafenib | Targeted therapy (MEK1) + targeted therapy (multiple kinases) | Colorectal Cancer | Phase 3 | NCT02788279 | ||
| Cobimetinib + venetoclax | Targeted therapy (MEK1) + targeted therapy (Bcl-2) | Myeloma | Phase 1, 2 | NCT03312530 | ||
| PD-L1 | Atezolizumab | Cobimetinib + vemurafenib | Targeted therapy (MEK1) + targeted therapy (BRAF) | Melanoma | Phase 1 | NCT01656642 |
| Rucaparib | Targeted therapy (PARP) | Gynecologic cancer; TNBC | Phase 1 | NCT03101280 | ||
| Lenalidomide + obinutuzumab | Targeted therapy (TNF-α) + targeted therapy (CD20) | Follicular lymphoma | Phase 1, 2 | NCT02631577 | ||
| Durvalumab | Bevacizumab | Anti-angiogenesis therapy | HER-2 negative breast cancer | Early Phase 1 | NCT02802098 | |
| Paclitaxel | Chemotherapy | TNBC | Phase 1, 2 | NCT02628132 | ||
| Azacitidine | Chemotherapy | Solid tumor | Phase 2 | NCT02811497 | ||
| Nab-paclitaxel + epirubicin + cyclophosphamide | Chemotherapy | TNBC | Phase 2 | NCT02685059 | ||
| Tremelimumab | CTLA-4 antibody | Head and Neck cancer | Phase 3 | NCT02369874 | ||
| Tremelimumab | CTLA-4 antibody | Solid tumor | Phase 1 | NCT02261220 | ||
| Tremelimumab | CTLA-4 antibody | HER2 negative breast cancer | Phase 2 | NCT02536794 | ||
| Tremelimumab | CTLA-4 antibody | Breast cancer; ovarian cancer; colorectal cancer; cervical cancer; RCC | Phase 1 | NCT01975831 | ||
| Tremelimumab | CTLA-4 antibody | Pancreatic ductal carcinoma | Phase 2 | NCT02558894 | ||
| Tremelimumab | CTLA-4 antibody | NSCLC | Phase 1 | NCT02000947 | ||
| Tremelimumab | CTLA-4 antibody | Head and neck cancer | Phase 1 | NCT02262741 | ||
| PD-L1 | Durvalumab | Tremelimumab | CTLA-4 antibody | Bladder cancer | Phase 2 | NCT03430895 |
| Tremelimumab | CTLA-4 antibody | Malignancy | Phase 1 | NCT02978482 | ||
| Tremelimumab | CTLA-4 antibody | Gastric cancer; gastroesophageal junction adenocarcinoma | Phase 1, 2 | NCT02340975 | ||
| Tremelimumab | CTLA-4 antibody | Colorectal cancer | Phase 2 | NCT03007407 | ||
| Tremelimumab | CTLA-4 antibody | Solid malignancy | Phase 1 | NCT02141347 | ||
| Tremelimumab | CTLA-4 antibody | Prostate cancer | Phase 2 | NCT03204812 | ||
| Tremelimumab + paclitaxel + carboplatin + etoposide + gemcitabine + nab-paclitaxel + 5FU + leucovorin + gemcitabine + cisplatin | CTLA-4 antibody + chemotherapy | Solid tumor | Phase 1 | NCT02658214 | ||
| Tremelimumab + SBRT | CTLA-4 antibody + radiotherapy | Pancreatic cancer | Phase 1, 2 | NCT02311361 | ||
| Mogamulizumab + tremelimumab | CTLA-4 antibody + targeted therapy (CCR4) | Solid tumor | Phase 1 | NCT02301130 | ||
| Tremelimumab + cetuximab + 5FU | CTLA-4 antibody + targeted therapy (EGFR) + chemotherapy | Head and Neck cancer | Phase 3 | NCT02551159 | ||
| Tremelimumab + AZD9150 | CTLA-4 antibody + targeted therapy (STAT3) | DLBCL | Phase 1 | NCT02549651 | ||
| HFRT + SBRT + tremelimumab | Radiotherapy + CTLA-4 antibody | SCLC | Phase 2 | NCT02701400 | ||
| PD-L1 | Durvalumab | Brain radiotherapy + stereotactic radiosurgery + tremelimumab + HER2 directed therapy | Radiotherapy + CTLA-4 antibody + other treatment | Breast cancer | n.a | NCT02563925 |
| Ablation + radiotherapy + tremelimumab | Surgery + radiotherapy + CTLA-4 antibody | Colorectal cancer | Phase 2 | NCT03122509 | ||
| Ensartinib | Targeted therapy (ALK) | NSCLC | Phase 1, 2 | NCT02898116 | ||
| Dabrafenib + trametinib | Targeted therapy (BRAF) + targeted therapy (MEK1/2) | Melanoma | Phase 1 | NCT02027961 | ||
| Ibrutinib | Targeted therapy (brutons tyrosine kinase) | Solid tumor | Phase 1, 2 | NCT02403271 | ||
| Ibrutinib | Targeted therapy (brutons tyrosine kinase) | DLBCL; follicular lymphoma | Phase 1, 2 | NCT02401048 | ||
| Daratumumab | Targeted therapy (CD38) | Myeloma | Phase 2 | NCT03000452 | ||
| Pexidartinib | Targeted therapy (CSF1R) | Pancreatic cancer; colorectal cancer | Phase 1 | NCT02777710 | ||
| AZD5069 + nab-paclitaxel + gemcitabine | Targeted therapy (CXCR2) + chemotherapy | Pancreatic ductal adenocarcinoma | Phase 1, 2 | NCT02583477 | ||
| Gefitinib | Targeted therapy (EGFR) | NSCLC | Phase 1 | NCT02088112 | ||
| Selumetinib + tremelimumab | Targeted therapy (MEK) + CTLA-4 antibody | Solid tumor | Phase 1 | NCT02586987 | ||
| Eribulin | Targeted therapy (microtubule) | Breast cancer; ovarian cancer | Phase 1 | NCT03430518 | ||
| Olaparib | Targeted therapy (PARP) | Squamous cell carcinoma of the head and neck | Phase 2 | NCT02882308 | ||
| PD-L1 | Durvalumab | Olaparib | Targeted therapy (PARP) | Bladder cancer | Phase 2 | NCT03534492 |
| Olaparib + bevacizumab | Targeted therapy (PARP) + anti-angiogenesis therapy | Solid tumor | Phase 1, 2 | NCT02734004 | ||
| Avelumab | Axitinib | Anti-angiogenesis therapy | GBM | Phase 2 | NCT03291314 | |
| Axitinib | Anti-angiogenesis therapy | RCC | Phase 1 | NCT02493751 | ||
| Axitinib | Anti-angiogenesis therapy | HCC | Phase 1 | NCT03289533 | ||
| Talazoparib + chemotherapy | Chemotherapy + targeted therapy (PARP) | Ovarian cancer | Phase 3 | NCT03642132 | ||
| HFRT | Radiotherapy | GMB | Phase 2 | NCT02968940 | ||
| SAR | Radiotherapy | NSCLC | Early Phase 1 | NCT03158883 | ||
| Cisplatin + 5-FU + mitomycin + radiation therapy | Radiotherapy + chemotherapy | Bladder cancer | Phase 2 | NCT03617913 | ||
| Radiotherapy + cetuximab | Radiotherapy + chemotherapy + targeted therapy (EGFR) | Squamous cell carcinoma of the head and neck | Phase 1 | NCT02938273 | ||
| Magrolimab | Targeted therapy (CD47) | Ovarian cancer | Phase 1 | NCT03558139 | ||
| Cetuximab + gemcitabine + cisplatin + carboplatin | Targeted therapy (EGFR) + chemotherapy | NSCLC | Phase 2 | NCT03717155 |
n.a. not applicable, SABR stereotactic ablative body radiosurgery, HFSRT hypofractionated stereotactic irradiation, SAR stereotactic ablative radiotherapy, RCC renal cell carcinoma, NSCLC non-small-cell lung cancer, TNBC triple-negative breast cancer, SCLC small-cell lung cancer, ED-SCLC extensive-stage disease small-cell lung cancer, MPM malignant pleural mesothelioma, AML acute myeloid leukemia, MBC metastatic breast cancer, BTC biliary tract carcinoma, GBM glioblastoma multiforme, CRPC castrate-resistant prostate cancer, DLBCL diffuse large B-cell lymphoma, GEJ Adenocarcinoma gastroesophageal junction adenocarcinoma, HCC hepatocellular carcinoma